SLP highlighted its impact on the pharma industry through support of the development of a majority of the drugs approved by the U.S. FDA in 2024.

The company said the funds would help it take advantage of its technology and expertise after its recent acquisition of ...

SLP’s technology and expertise accelerates drug development and supports critical advancements in global healthcare. Simulations Plus, Inc. (Nasdaq: SLP) (“Simul ...